Stimuvax Will Become Decision Resources' Proprietary Clinical Gold Standard For The Treatment Of Locally Advanced Non-Small-Cell Lung Cancer

A Drug that Improves Median Overall Survival When Used in Conjunction with Radiotherapy/Chemotherapy Would Earn Greater Patient Share in the U.S. Than Europe for the Treatment of Unresectable Locally Advanced Non-Small-Cell Lung Cancer, According to a New Report from Decision Resources

For more information, contact:

Christopher Comfort
Decision Resources
781-296-2597
[email protected]

Latest Press Release on Cancer News

Huma and Merck KGaA, Darmstadt, Germany Launch Innovative App to Support Bladder Cancer Patients

LONDON , April 29, 2024 /PRNewswire/ -- Huma Therapeutics ("Huma"), a leader in global digital health innovation, together with Merck KGaA, Darmstadt, Germany , a leading science...

The Melanoma Research Foundation to host the DC Miles for Melanoma 5K

The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, support...

Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC

SUZHOU, China , April 26, 2024 /PRNewswire/ -- Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food ...

Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers

The second DMC review recommends the continuation of dose escalation in the clinical trial as per protocol. The interim safety assessment was based on the review of safety data from 1...

2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor

SHANGHAI , April 25, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase I/II clinical...